Commentary on “Humanization of an Anti-VEGF Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders”

See related article by Presta et al., Cancer Res 1997;57:4593–99.Visit the Cancer Research 75th Anniversary timeline.The highlighted article describes the engineering of a molecule that for the first time allowed testing the hypothesis that blocking VEGF-mediated angiogenesis may confer a benefit on human patients (1). Twenty years later, the reagent described in our study, known today as bevacizumab or Avastin, represents a standard of therapy...